Frontiers in Pediatrics · 2020 · 28 citations · 13 references
MedicineInternal MedicineMolecular GeneticsHepatologyMedical GeneticsMolecular DiagnosticsBiliary Tract DiseaseBiliary Tract DisordersChronic Liver DiseaseCirrhosisHepatic PathologyLiver DiseaseClinical Utility AnalysisClinical Utility AssessmentGenetic Cholestatic DisordersGenetic Liver DiseasePathogenic Germline Variants
Objectives: To evaluate the clinical utility of panel-based next-generation sequencing (NGS) in diagnostic approach of monogenic cholestatic liver diseases. Methods: 22 patients with diagnosis of chronic cholestatic liver disease of an unknown etiology underwent NGS of targeted genes panel including 53 items related to cholestatic liver disorders. Group 1 included 5 patients, prospectively recruited, and hospitalized from January to December 2017, while group 2 included 17 patients, retrospectively recruited, and hospitalized from 2010 to 2017 with diagnosis of low gamma-glutamyl transferase (low-GGT) progressive familial intrahepatic cholestasis (PFIC) phenotype (group 2a, 11 patients) or indeterminant cholestatic liver cirrhosis (group 2b, 6 patients). Results: Among 22 patients enrolled into the study, 21 various pathogenic variants (including 11 novel) in 5 different genes (including ABCB11, ABCB4, TJP2, DGUOK, CYP27A1) were identified. The molecular confirmation was obtained in 15 out of 22 patients (68%). Conclusions: Panel-based NGS appears to be a very useful tool in diagnosis of monogenic cholestatic liver disorders when extrahepatic causes have been primarily excluded. NGS presented the highest diagnosis rate to identify the molecular background of cholestatic liver diseases presenting with a low-GGT PFIC phenotype.
13
Mutations in TJP2 cause progressive cholestatic liver disease
Melissa Sambrotta, Sandra Strautnieks, Efterpi Papouli et al. · Nature Genetics · 2014 · 293 citations · Full text